Anti-hcv monoclonal antibody as a medicament for the theraputic treatment and prevention of hcv infections
AssigneePomona Ricerca S.r.l.
InventorsRoberto Burioni, Massimo Clememti
Life of this patent
Estimating the term…
Abstract
The present invention relates to the monoclonal antibody e20 or a functional fragment thereof as a medicament for the therapeutic treatment and prevention of HCV infections. The e20 antibody is able to bind all of the known HCV genotypes and exhibits a strong neutralising activity against the virus, in particular towards genotypes 1a, 1b, 2a, and 4. A pharmaceutical composition is also described for the treatment or prevention of HCV infections, which comprises the monoclonal antibody e20 or a functional fragment thereof, and pharmaceutically acceptable excipients, carriers or diluents.
Claims17
A monoclonal antibody or fragment thereof, capable of binding the HCV E2 glycoprotein from a plurality of different HCV genotypes, as a medicament for the therapeutic treatment or prevention of HCV infections, wherein the monoclonal antibody or fragment thereof comprises at least one heavy chain variable region comprising the amino acid sequence SEQ ID NO:1 or a sequence at least 90% identical to SEQ ID NO:1 and at least one light chain variable region comprising the amino acid sequence SEQ ID NO:2 or a sequence at least 90% identical to SEQ ID NO:2.
(canceled)
Dependencies are inferred from the claim text.